Form 4 holding
Chief Business and Commercial Officer, Proprietary Drugs
Athenex, Inc.
- Security class
- Common Stock
- Shares / value
- 4,140
- Estimated value
- $5,630
- Report date
- 05 May 2023
- Price
- $1.36
- Ownership
- Direct
Timothy DeVere Cook
Insider Reports History
- Reporting-owner location
- Buffalo, NY
- Latest reporting-owner signature
-
/s/Steven Adams, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for Timothy DeVere Cook
Form 4 holding
Chief Business and Commercial Officer, Proprietary Drugs
Athenex, Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 3,750
- Estimated value
- Report date
- 05 May 2023
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,750
Form 4 holding
Chief Business and Commercial Officer, Proprietary Drugs
Athenex, Inc.
- Security class
- Restricted Stock Units
- Shares / value
- 338
- Estimated value
- Report date
- 05 May 2023
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 338
Insider Reports Filed by Timothy DeVere Cook
4
Athenex, Inc.
- Report period
- 05 May 2023
- Transactions
- 1
- Transaction value
- +$500
- Accepted by SEC
- 08 May 2023, 16:29
- Role
- Chief Business and Commercial Officer, Proprietary Drugs
- Next action
- Open filing details
4
Athenex, Inc.
- Report period
- 21 Apr 2023
- Transactions
- 1
- Transaction value
- +$500
- Accepted by SEC
- 24 Apr 2023, 16:29
- Role
- Chief Business and Commercial Officer, Proprietary Drugs
- Next action
- Open filing details
4
Athenex, Inc.
- Report period
- 07 Apr 2023
- Transactions
- 1
- Transaction value
- +$500
- Accepted by SEC
- 11 Apr 2023, 16:36
- Role
- Chief Business and Commercial Officer, Proprietary Drugs
- Next action
- Open filing details
4
Athenex, Inc.
- Report period
- 24 Mar 2023
- Transactions
- 1
- Transaction value
- +$500
- Accepted by SEC
- 27 Mar 2023, 16:33
- Role
- Chief Business and Commercial Officer, Proprietary Drugs
- Next action
- Open filing details
4
Athenex, Inc.
- Report period
- 10 Mar 2023
- Transactions
- 1
- Transaction value
- +$501
- Accepted by SEC
- 13 Mar 2023, 16:41
- Role
- Chief Business and Commercial Officer, Proprietary Drugs
- Next action
- Open filing details
4
Athenex, Inc.
- Report period
- 24 Feb 2023
- Transactions
- 1
- Transaction value
- +$499
- Accepted by SEC
- 27 Feb 2023, 16:01
- Role
- Chief Business and Commercial Officer, Proprietary Drugs
- Next action
- Open filing details
4
Athenex, Inc.
- Report period
- 10 Feb 2023
- Transactions
- 1
- Transaction value
- +$500
- Accepted by SEC
- 13 Feb 2023, 15:54
- Role
- Chief Business and Commercial Officer, Proprietary Drugs
- Next action
- Open filing details
4
Athenex, Inc.
- Report period
- 27 Jan 2023
- Transactions
- 1
- Transaction value
- +$500
- Accepted by SEC
- 31 Jan 2023, 07:19
- Role
- Chief Business and Commercial Officer, Proprietary Drugs
- Next action
- Open filing details
4
Athenex, Inc.
- Report period
- 13 Jan 2023
- Transactions
- 1
- Transaction value
- +$500
- Accepted by SEC
- 17 Jan 2023, 07:03
- Role
- Chief Business and Commercial Officer, Proprietary Drugs
- Next action
- Open filing details
4
Athenex, Inc.
- Report period
- 30 Dec 2022
- Transactions
- 1
- Transaction value
- +$500
- Accepted by SEC
- 03 Jan 2023, 06:57
- Role
- Chief Business and Commercial Officer, Proprietary Drugs
- Next action
- Open filing details
4
Athenex, Inc.
- Report period
- 16 Dec 2022
- Transactions
- 1
- Transaction value
- +$500
- Accepted by SEC
- 20 Dec 2022, 07:36
- Role
- Chief Business and Commercial Officer, Proprietary Drugs
- Next action
- Open filing details
4
Athenex, Inc.
- Report period
- 02 Dec 2022
- Transactions
- 1
- Transaction value
- +$500
- Accepted by SEC
- 06 Dec 2022, 15:15
- Role
- Chief Business and Commercial Officer, Proprietary Drugs
- Next action
- Open filing details
4
Athenex, Inc.
- Report period
- 18 Nov 2022
- Transactions
- 1
- Transaction value
- +$500
- Accepted by SEC
- 21 Nov 2022, 15:22
- Role
- Chief Business and Commercial Officer, Proprietary Drugs
- Next action
- Open filing details
4
Athenex, Inc.
- Report period
- 04 Nov 2022
- Transactions
- 1
- Transaction value
- +$500
- Accepted by SEC
- 08 Nov 2022, 06:44
- Role
- Chief Business and Commercial Officer, Proprietary Drugs
- Next action
- Open filing details
4
Athenex, Inc.
- Report period
- 21 Oct 2022
- Transactions
- 1
- Transaction value
- +$500
- Accepted by SEC
- 24 Oct 2022, 16:45
- Role
- Chief Business and Commercial Officer, Proprietary Drugs
- Next action
- Open filing details
4
Athenex, Inc.
- Report period
- 07 Oct 2022
- Transactions
- 1
- Transaction value
- +$500
- Accepted by SEC
- 12 Oct 2022, 08:18
- Role
- Chief Business and Commercial Officer, Proprietary Drugs
- Next action
- Open filing details
4
Athenex, Inc.
- Report period
- 23 Sep 2022
- Transactions
- 1
- Transaction value
- +$500
- Accepted by SEC
- 27 Sep 2022, 16:25
- Role
- Chief Business and Commercial Officer, Proprietary Drugs
- Next action
- Open filing details
4
Athenex, Inc.
- Report period
- 16 Sep 2022
- Transactions
- 3
- Transaction value
- -$224
- Accepted by SEC
- 19 Sep 2022, 16:24
- Role
- Chief Business and Commercial Officer, Proprietary Drugs
- Next action
- Open filing details
4
Athenex, Inc.
- Report period
- 09 Sep 2022
- Transactions
- 1
- Transaction value
- +$500
- Accepted by SEC
- 12 Sep 2022, 17:45
- Role
- Chief Business and Commercial Officer, Proprietary Drugs
- Next action
- Open filing details
4
Athenex, Inc.
- Report period
- 26 Aug 2022
- Transactions
- 1
- Transaction value
- +$500
- Accepted by SEC
- 29 Aug 2022, 16:29
- Role
- Chief Business and Commercial Officer, Proprietary Drugs
- Next action
- Open filing details
4
Athenex, Inc.
- Report period
- 12 Aug 2022
- Transactions
- 1
- Transaction value
- +$500
- Accepted by SEC
- 15 Aug 2022, 18:49
- Role
- Chief Business and Commercial Officer, Proprietary Drugs
- Next action
- Open filing details
4
Athenex, Inc.
- Report period
- 29 Jul 2022
- Transactions
- 1
- Transaction value
- +$500
- Accepted by SEC
- 01 Aug 2022, 16:24
- Role
- Chief Business and Commercial Officer, Proprietary Drugs
- Next action
- Open filing details
4
Athenex, Inc.
- Report period
- 20 Jul 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 21 Jul 2022, 17:20
- Role
- Chief Business and Commercial Officer, Proprietary Drugs
- Next action
- Open filing details
4
Athenex, Inc.
- Report period
- 15 Jul 2022
- Transactions
- 1
- Transaction value
- +$500
- Accepted by SEC
- 18 Jul 2022, 16:19
- Role
- Chief Business and Commercial Officer, Proprietary Drugs
- Next action
- Open filing details
4
Athenex, Inc.
- Report period
- 01 Jul 2022
- Transactions
- 1
- Transaction value
- +$500
- Accepted by SEC
- 05 Jul 2022, 16:14
- Role
- Chief Business and Commercial Officer, Proprietary Drugs
- Next action
- Open filing details
4
Athenex, Inc.
- Report period
- 17 Jun 2022
- Transactions
- 1
- Transaction value
- +$500
- Accepted by SEC
- 21 Jun 2022, 16:22
- Role
- Chief Business and Commercial Officer, Proprietary Drugs
- Next action
- Open filing details
4
Athenex, Inc.
- Report period
- 03 Jun 2022
- Transactions
- 1
- Transaction value
- +$500
- Accepted by SEC
- 06 Jun 2022, 16:15
- Role
- Chief Business and Commercial Officer, Proprietary Drugs
- Next action
- Open filing details
4
Athenex, Inc.
- Report period
- 20 May 2022
- Transactions
- 1
- Transaction value
- +$500
- Accepted by SEC
- 23 May 2022, 16:32
- Role
- Chief Business and Commercial Officer, Proprietary Drugs
- Next action
- Open filing details
4
Athenex, Inc.
- Report period
- 06 May 2022
- Transactions
- 1
- Transaction value
- +$500
- Accepted by SEC
- 06 May 2022, 17:05
- Role
- Chief Business and Commercial Officer, Proprietary Drugs
- Next action
- Open filing details
4
Athenex, Inc.
- Report period
- 22 Apr 2022
- Transactions
- 1
- Transaction value
- +$500
- Accepted by SEC
- 29 Apr 2022, 16:28
- Role
- Chief Business and Commercial Officer, Proprietary Drugs
- Next action
- Open filing details
4
Athenex, Inc.
- Report period
- 08 Apr 2022
- Transactions
- 1
- Transaction value
- +$500
- Accepted by SEC
- 11 Apr 2022, 18:33
- Role
- Chief Business and Commercial Officer, Proprietary Drugs
- Next action
- Open filing details
4
Athenex, Inc.
- Report period
- 25 Mar 2022
- Transactions
- 1
- Transaction value
- +$500
- Accepted by SEC
- 29 Mar 2022, 17:14
- Role
- Chief Business and Commercial Officer, Proprietary Drugs
- Next action
- Open filing details
3
Athenex, Inc.
- Report period
- 22 Dec 2021
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 10 Jan 2022, 15:31
- Role
- Chief Business and Commercial Officer, Proprietary Drugs Exhibit List: Exhibit 24.1 - Power of Attorney
- Next action
- Open filing details